ProStrakan markets a range of products in a number of key EU territories.  Our business model allows for revenues arising from product sales to be ploughed into our R&D operations where new medicines can be developed for the benefit of more and more patients in future.

ProStrakan's current strategic focus is on the women's health, the ageing male and bone diseases therapeutic areas. As ProStrakan has grown and evolved over the years, we have acquired and merged with a number of companies which has led to us selling a range of products, some of which lie beyond our prime therapeutic focus but are still providing help to many patients.

For information on which products are marketed in which territory, please click on the individual country links below.  Please note that the information provided is specific to residents of individual countries because each product may not be approved for marketing in other countries or the licensed prescribing information may differ from country to country.

Below is a chart giving details of our promoted products.